Back to search
FDAFDA · Food and drugs·Recall number D-1328-2022

Difluprednate Ophthalmic Emulsion 0.05%, For Ophthalmic Use Only, Sterile, 5 mL bottles, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35.

Published August 17, 2022 · Recall initiated: August 2, 2022

Summary

FDA records drug Class II recall D-1328-2022, published August 17, 2022 and initiated August 2, 2022. Recalling firm: CIPLA; Status: Terminated; Reported quantity: 7,992 bottles; Lot: Lot # DEG3LC2, Exp 05/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: Complaints received of defective container closure.

What to do

Voluntary: Firm initiated · Letter

Get an email if DIFLUPREDNATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIFLUPREDNATE
Manufacturer
CIPLA
Distributor
Nationwide in the USA
Lot
Lot # DEG3LC2, Exp 05/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Difluprednate Ophthalmic Emulsion 0.05%, For Ophthalmic Use Only, Sterile, 5 mL bottles, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35. recalled?

Yes. FDA published recall D-1328-2022 on August 17, 2022. Reported hazard: Lack of Assurance of Sterility: Complaints received of defective container closure.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIFLUPREDNATE.